HENGAN INT'L (01044): Li Weiliang has been appointed as Executive Director, Chief Financial Officer, and Authorized Representative.
Hengan International (01044) announced that, effective from September 9, 2026, due to internal personnel changes, Ms. Shi Xiaoli will no longer serve as the authorized representative of the company under Rule 3.05 of the Securities Listing Rules of The Stock Exchange of Hong Kong Limited, as well as the authorized representative of the company to accept any legal documents or notices served on the company under Part 16 of the Companies Ordinance (collectively referred to as the authorized representatives). However, Ms. Shi will continue to serve as the company secretary of the company.
HENGAN INT'L (01044) announced that, effective September 9, 2026, due to internal personnel changes, Ms. Shi Xiaoli will no longer serve as the authorized representative of the company under Rule 3.05 of the Listing Rules of The Stock Exchange of Hong Kong Limited, as well as the authorized representative of the company under Section 16 of the Companies Ordinance for receiving any legal documents or notices served on the company (collectively referred to as the authorized representatives), but Ms. Shi will continue to serve as the company secretary.
Effective September 9, 2026, Mr. Li Weiliang has been appointed as the executive director, Chief Financial Officer of the Group, and authorized representative of the company. As of September 9, 2026, he will also become a member of the Environmental, Social and Governance Committee and the Share Incentive Committee.
Related Articles

HUITONGDA NET (09878) Mid-term Performance Interpretation for 2026: Smart Supply Chain Lays the Foundation as Fast-Moving Consumer Goods Retail Chain New Curve Accelerates Formation

HK Stock Market Move | SHINEWAY PHARM (02877) rose over 9% in the afternoon as the company participates in the 2026 medical insurance national negotiation bidding with multiple proprietary Chinese medicine products.

Orient: Siasun Robot & Automation Industry's mass production prosperity is on the rise, with OEM manufacturers performing relatively better.
HUITONGDA NET (09878) Mid-term Performance Interpretation for 2026: Smart Supply Chain Lays the Foundation as Fast-Moving Consumer Goods Retail Chain New Curve Accelerates Formation

HK Stock Market Move | SHINEWAY PHARM (02877) rose over 9% in the afternoon as the company participates in the 2026 medical insurance national negotiation bidding with multiple proprietary Chinese medicine products.

Orient: Siasun Robot & Automation Industry's mass production prosperity is on the rise, with OEM manufacturers performing relatively better.

RECOMMEND





